Showing results (2531-2540 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 27, 2013
Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cellsMancang Gu, Yanke Yu, G M Kamal B Gunaherath, et al.
Investigational New Drugs|November 13, 2014
Pharmacokinetic study of aldoxorubicin in patients with solid tumorsMonica M Mita, Ronald B Natale, Edward M Wolin, et al.
Investigational New Drugs|November 23, 2014
The marine natural product microsclerodermin A is a novel inhibitor of the nuclear factor kappa B and induces apoptosis in pancreatic cancer cellsEsther A Guzmán, Kelly Maers, Jill Roberts, et al.
Investigational New Drugs|November 20, 2020
Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumorsLin Yu, Xi Yang, Nan Huang, et al.
Investigational New Drugs|November 24, 2020
4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancerBlake A Jacobson, Zeeshan Ahmad, Sierra Chen, et al.
Investigational New Drugs|February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignanciesJ Nehra, P A Bradbury, P M Ellis, et al.
Investigational New Drugs|January 8, 2020
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignanciesToshihiko Doi, Narikazu Boku, Yusuke Onozawa, et al.
Investigational New Drugs|September 1, 1988
Preclinical antitumor activity of batracylin (NSC 320846)J Plowman, K D Paull, G Atassi, et al.
Investigational New Drugs|September 1, 1988
Phase I trial of the polyelectrolyte carbetimer administered i.v. once every four weeksM Fromm, W E Berdel, H D Schick, et al.
Investigational New Drugs|March 5, 2020
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancerHiroto Inoue, Akira Ono, Takanori Kawabata, et al.
Pageof 372